HLA-F-modified cells and methods

US12076346B2 · kind B2 · utility

Assignee

• APPLIED STEMCELL, INC. · US

Inventors

• Ruby Yanru TSAI · Milpitas, US
• Alfonso FARRUGGIO · Stanford, US
• Xiuling CHI · San Jose, US
• Kai Wang · Shanghai, CN

Key dates

• Filing date: Feb 9, 2023
• Grant date: Sep 3, 2024
• Expiry date: Feb 9, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.